Aptevo Therapeutics jumps after securing $60 million equity line of credit [Seeking Alpha]
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality [Yahoo! Finance]
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.